Nutritional limitation sensitizes mammalian cells to GSK-3β inhibitors and leads to growth impairment
- PMID: 21435461
- PMCID: PMC3078455
- DOI: 10.1016/j.ajpath.2010.12.047
Nutritional limitation sensitizes mammalian cells to GSK-3β inhibitors and leads to growth impairment
Abstract
The serine/threonine kinase GSK-3β was initially described as a key enzyme involved in glucose metabolism, but it is now known to regulate a wide range of biological processes, including proliferation and apoptosis. We previously reported a transformation-dependent cell death induced by glucose limitation in K-ras-transformed NIH3T3. To address the mechanism of this phenomenon, we analyzed GSK-3β regulation in these cells in conditions of high versus low glucose availability. We found that glucose depletion caused a marked inhibition of GSK-3β through posttranslational mechanisms and that this inhibition was much less pronounced in normal cells. Further inhibition of GSK-3β with lithium chloride, combined with glucose shortage, caused specific activation of AMP-activated protein kinase and significant suppression of proliferation in transformed but not normal cells. The cooperative effect of lithium and low glucose availability on cell growth did not seem to depend exclusively on ras pathway activation because two human cell lines, A549 and MDA-MB-231, both harboring an activated ras gene, showed very different sensitivity to lithium. These findings thus provide a rationale to further analyze the biochemical bases for combined glucose deprivation and GSK-3β inhibition as a new approach to control transformed cell growth.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures






Similar articles
-
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.Mol Cancer Ther. 2007 Mar;6(3):1151-8. doi: 10.1158/1535-7163.MCT-06-0665. Mol Cancer Ther. 2007. PMID: 17363508
-
Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.Exp Hematol. 2010 Oct;38(10):908-921.e1. doi: 10.1016/j.exphem.2010.06.001. Epub 2010 Jun 9. Exp Hematol. 2010. PMID: 20540984
-
Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.J Natl Cancer Inst. 2012 May 16;104(10):749-63. doi: 10.1093/jnci/djs210. Epub 2012 Apr 24. J Natl Cancer Inst. 2012. PMID: 22534782 Free PMC article.
-
Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.J Biol Chem. 2004 Sep 17;279(38):39541-54. doi: 10.1074/jbc.M403449200. Epub 2004 Jul 13. J Biol Chem. 2004. PMID: 15252041
-
GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells.Prostate. 2016 Feb;76(2):172-83. doi: 10.1002/pros.23106. Epub 2015 Oct 6. Prostate. 2016. PMID: 26440826 Free PMC article.
Cited by
-
Glucose deprivation triggers protein kinase C-dependent β-catenin proteasomal degradation.J Biol Chem. 2015 Apr 10;290(15):9863-73. doi: 10.1074/jbc.M114.606756. Epub 2015 Feb 17. J Biol Chem. 2015. PMID: 25691573 Free PMC article.
-
LiCl Treatment Induces Programmed Cell Death of Schwannoma Cells through AKT- and MTOR-Mediated Necroptosis.Neurochem Res. 2017 Aug;42(8):2363-2371. doi: 10.1007/s11064-017-2256-2. Epub 2017 Apr 10. Neurochem Res. 2017. PMID: 28397069
-
GSK3β signaling is involved in ultraviolet B-induced activation of autophagy in epidermal cells.Int J Oncol. 2012 Nov;41(5):1782-8. doi: 10.3892/ijo.2012.1620. Epub 2012 Sep 5. Int J Oncol. 2012. PMID: 22961228 Free PMC article.
-
Steroid receptor coactivator 1 is an integrator of glucose and NAD+/NADH homeostasis.Mol Endocrinol. 2014 Mar;28(3):395-405. doi: 10.1210/me.2013-1404. Epub 2014 Jan 17. Mol Endocrinol. 2014. PMID: 24438340 Free PMC article.
-
Dynamic biological changes in fibroblasts during hypertrophic scar formation and regression.Int Wound J. 2016 Apr;13(2):257-62. doi: 10.1111/iwj.12283. Epub 2014 May 7. Int Wound J. 2016. PMID: 24802644 Free PMC article.
References
-
- Kockeritz L., Doble B., Patel S., Woodgett J.R. Glycogen synthase kinase-3: an overview of an over-achieving protein kinase. Curr Drug Targets. 2006;11:1377–1388. - PubMed
-
- Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev. 2008;28:773–796. - PubMed
-
- Manoukian A.S., Woodgett J.R. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res. 2002;84:203–229. - PubMed
-
- Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev. 1999;9:15–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous